Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue
Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue
复制标题
DOI：
10.1016/j.oraloncology.2004.01.006
复制
发表时间：
2004-09-01
期刊：
影响因子：
4.8
通讯作者：
Feinmesser, R
中科院分区：
文献类型：
--
作者：
Guttman, D;Stern, Y;Feinmesser, R
舌鳞状细胞癌(SCC)的特点是病程不可预测，从相对良性到高度局部侵袭性生长和转移不等。治疗指南已经根据TNM分期制定，但它们并不总是准确地预测临床结果。本研究旨在探讨降解细胞外基质及其抑制物(TIMPs)和血管生成因子(F8和CD-34)的基质金属蛋白酶(MMPs)在舌癌组织中的表达及其与临床病理特征和患者预后的关系。MMP9和TIMP 1高表达分别占60.9%和65.2%。肿瘤侵犯邻近肌肉、淋巴结转移和随访结束时的疾病状态与CD-34标记的微血管计数呈正相关，而与MMP9或TIMP-1的高表达无关。然而，肿瘤组织中的血管化程度是疾病侵袭性的指标，可以作为选择患者进行更深入治疗的基础。(C)2004爱思唯尔有限公司。保留所有权利。
Squamous cell carcinoma (SCC) of the tongue is characterized by an unpredictable course, ranging from relatively benign to a high degree of locally aggressive growth and metastasis. Treatment guidelines have been developed according to TNM stage, but they do not always accurately predict clinical outcome. The aim of the present study was to evaluate the expression of the matrix metalloproteinases (MMPs) that degrade the extracellular matrices, their inhibitors (TIMPs), and angiogenic factors (factor-8 and CD-34) in tumor cells and to correlate these findings with the clinicopathological features and patient outcome.Tissue specimens from 23 patients with primary SCC of the tongue were immunohistochemically stained for these markers. High expressions of MMP-9 and TIMP-1 were detected in 60.9% and 65.2% of the specimens, respectively. Tumor invasion to adjacent muscle, lymph node metastasis, and disease status at the end of follow-up were positively correlated with the microvesset count using the CD-34 marker, but not with high expression of MMP-9 or TIMP-1.Expression of MMP-9 and TIMP-1 fails to predict aggressiveness in SCC of the tongue. However, the degree of vascularization in tumor tissue is indicative of disease aggressiveness and might be used as a basis for patient selection for more intensive therapy. (C) 2004 Elsevier Ltd. All rights reserved.